News 27.12.2019 Zurich-Schlieren, Switzerland, December 27, 2019. Molecular Partners AG (SIX:MOLN), a clinicalstage biotech company pioneering the use of DARPin® therapeutics to treat serious diseases, announces the receipt of Orphan Drug Designation by the US Food and Drug Administration (FDA) for its novel therapeutic, MP0250, for the treatment of Multiple Myeloma. MP0250 is...
News 07.12.2019 Zurich-Schlieren, Switzerland, December 7, 2019. Molecular Partners AG (SIX: MOLN), a clinical-stage biotech company pioneering the use of DARPin® therapeutics to treat serious diseases, today announced a poster presentation at the American Society of Hematology 61st Annual Meeting in Orlando, FL, highlighting the activity of its tri-specific DARPin® drug candidate, MP0250, in patients undergoing...
News 04.12.2019 Schlieren (Zurich), Switzerland, December 3, 2019 – Kuros Biosciences (SIX: KURN) (the Company or Kuros) announces the final number of Offered Shares and gross proceeds from the Rights Offering and Share Offering, first announced on November 19, 2019, in which a total of up to 6,405,022 new registered shares of...
News 20.11.2019 URDORF (Zurich), Switzerland, November 18, 2019 / B3C newswire / -- Securecell today announced that it has introduced Sephara, a high performance in-situ filtration membrane for applications in bioprocess sampling and perfusion processes for use in selected bioprocess laboratories. Interested users can participate in an early access program for the...
News 31.10.2019 Zurich-Schlieren, October 31, 2019. Molecular Partners AG (SIX: MOLN), a clinical-stage biotech company that is developing a new class of drugs known as DARPin® therapies*, announced today its Interim Management Statement for the period ending September 30, 2019. “Abicipar represents the first DARPin® therapeutic to be accepted for review by FDA...